TP53 and cancer: Such readouts (the differential staining of mortalin and the change of p53 localization) were previously reported as criteria for the selection of an anti-cancer molecule with the potentiality to abrogate mortalin-p53 interaction (Gao et al., 2012; Putri et al., 2019).